Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncternal Therapeutics (ONCT – Research Report) and 180 Life Sciences (ATNF – Research Report).
Oncternal Therapeutics (ONCT)
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Oncternal Therapeutics, with a price target of $3.50. The company’s shares closed last Wednesday at $1.12, close to its 52-week low of $0.69.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncternal Therapeutics with a $8.50 average price target, implying a 665.8% upside from current levels. In a report issued on August 9, Brookline Capital Markets also maintained a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
180 Life Sciences (ATNF)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Hold rating on 180 Life Sciences. The company’s shares closed last Wednesday at $1.10, close to its 52-week low of $0.79.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The the analyst consensus on 180 Life Sciences is currently a Hold rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ONCT:
- Alithya reports another quarter of strong revenue growth for Q1 fiscal 2023
- Maxim Group Keeps Their Buy Rating on Cidara Therapeutics (CDTX)
- Maxim Group Keeps Their Buy Rating on PaySign (PAYS)
- Wedbush Sticks to Their Buy Rating for Cathay General Bancorp (CATY)
- Man Group PLC : Form 8.3 – Caretech Holdings plc
